The IRIS Study has shown that Gleevec is far superior to the previous drugs. Even if people initially responded to Interferon, Ara-C, and Hydroxyurea, these responses were not as deep and durable as with Gleevec, so long term survival rates were poor when compared to the 95% overall survival rate for Gleevec. Besides the lack of long term benefit, many people could not tolerate the side effects from those drugs. Hydroxyurea is still used for some at initial diagnosis when WBC counts are extremely high to gain a rapid reduction in leukemia cells, but then Gleevec is used soon after that. There are a few who beat the odds on earlier drug therapy, but they were rare cases, and their quality of life was often poor.
http://www.sciencedaily.com/releases/2007/12/071210094338.htm --~--~---------~--~----~------------~-------~--~----~ [CMLHope] A support group of http://cmlhope.com ------------------------------------------------- You received this message because you are subscribed to the Google Groups "CMLHope" group. To post to this group, send email to [email protected] To unsubscribe from this group, send email to [EMAIL PROTECTED] For more options, visit this group at http://groups.google.com/group/CMLHope -~----------~----~----~----~------~----~------~--~---
